Our finding of PLK1 inhibitor being effective in inhibition of ACHN OIP5 tumor growth may have significant clinical applications in treating metastatic pRCC with OIP5 upregulation; this will offer a venue for potential utilization of personalized therapy in pRCC. This evidence concerns the gene OIP5 and neoplasm.